Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Apr;9(5):677-86.
doi: 10.1517/14656566.9.5.677.

Warfarin therapy: in need of improvement after all these years

Stephen E Kimmel  1
Affiliations
Review

Warfarin therapy: in need of improvement after all these years

Stephen E Kimmel. Expert Opin Pharmacother. 2008 Apr.

Abstract

Background: Warfarin therapy has been used clinically for over 60 years, yet continues to be problematic because of its narrow therapeutic index and large inter-individual variability in patient response. As a result, warfarin is a leading cause of serious medication-related adverse events, and its efficacy is also suboptimal.

Objective: To review factors that are responsible for variable response to warfarin, including clinical, environmental, and genetic factors, and to explore some possible approaches to improving warfarin therapy.

Results: Recent efforts have focused on developing dosing algorithms that included genetic information to try to improve warfarin dosing. These dosing algorithms hold promise, but have not been fully validated or tested in rigorous clinical trials. Perhaps equally importantly, adherence to warfarin is a major problem that should be addressed with innovative and cost-effective interventions.

Conclusion: Additional research is needed to further test whether interventions can be used to improve warfarin dosing and outcomes.

PubMed Disclaimer

References

    1. Laupacis A, Albers G, Dalen J, et al. Antithrombotic therapy in atrial fibrillation. Chest. 1998;114:579S–589S. - PubMed
    1. Abusaada K, Sharma SB, Jaladi R, Ezekowitz MD. Epidemiology and management of new-onset atrial fibrillation. Am J Manag Care. 2004;10:S50–7. - PubMed
    1. Goldhaber SZ. Pulmonary embolism. N Engl J Med. 1998;339:93–104. - PubMed
    1. Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis. 1975;17:257–70. - PubMed
    1. Rosamond WD, Folsom AR, Chambless LE, et al. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke. 1999;30:736–43. - PubMed

MeSH terms